Selected article for: "syndrome virus and virus structure"
Author: Kandimalla, Ramesh; John, Albin; Abburi, Chandrika; Vallamkondu, Jayalakshmi; Reddy, P. Hemachandra
Title: Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics
  • Cord-id: y87tq9wu
  • Document date: 2020_7_15
    • ID: y87tq9wu
    Snippet: The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The struc
    Document: The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure: see text]

    Search related documents:
    Co phrase search for related documents
    • acute sars respiratory syndrome coronavirus and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute sars respiratory syndrome coronavirus and load clearance: 1, 2, 3, 4, 5
    • acute sars respiratory syndrome coronavirus and loading dose: 1, 2
    • acute sars respiratory syndrome coronavirus and lopinavir ritonavir ribavirin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • acute sars respiratory syndrome coronavirus and low dosage: 1, 2, 3, 4
    • acute sars respiratory syndrome coronavirus and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
    • acute sars respiratory syndrome coronavirus and lysosomal activity: 1, 2
    • acute sars respiratory syndrome coronavirus and lysosomal endosomal: 1, 2, 3, 4, 5, 6
    • acute sars respiratory syndrome coronavirus and lysosomal endosomal activity: 1
    • liver cirrhosis and lupus erythematosus: 1
    • liver cirrhosis and lysosomal activity: 1
    • liver kidney and lopinavir ritonavir ribavirin: 1
    • liver kidney and lupus erythematosus: 1, 2
    • liver kidney and lysosomal endosomal: 1